Sign In
Buy MRK
$120.78
+1.69 (+1.41%)
At Close: Jun 11, 2026
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
09:30am, Sunday, 07'th Jun 2026
After years of lagging the market, healthcare may be taking on a new role in investor portfolios.
The Smartest Dividend ETF to Buy With $1,000 Right Now -- and It's Up 19% in 2026
06:30pm, Saturday, 06'th Jun 2026
This ETF's dividend yield was recently a solid 3.25%, about three times that of the S&P 500. Its growth rate has been better than that of many dividend-focused funds.
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
06:19pm, Friday, 05'th Jun 2026
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.
Why Health Care's Seasonal Tailwind Looks Especially Compelling This Year
12:50pm, Friday, 05'th Jun 2026
The seasonal strength lines up with major medical and scientific conferences that cluster during this period.
Merck & Co.: Why The Market Is Right To Start Buying Into Post-Keytruda Promise
12:25pm, Friday, 05'th Jun 2026
Merck & Co., Inc. has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite looming patent expiry in 2028. MRK has aggressively pursued acquisitions and partners
Dividend ETFs: SCHD Boasts a Larger Dividend Yield, While VIG Has Lower Fees
10:39am, Friday, 05'th Jun 2026
Explore how sector weightings and stock selection shape risk and return for these two leading dividend ETFs, each with distinct strategies and top holdings.
Merck (MRK) Recently Broke Out Above the 20-Day Moving Average
10:36am, Friday, 05'th Jun 2026
From a technical perspective, Merck (MRK) is looking like an interesting pick, as it just reached a key level of support. MRK recently overtook the 20-day moving average, and this suggests a short-ter
Merck (MRK) Crossed Above the 50-Day Moving Average: What That Means for Investors
10:31am, Friday, 05'th Jun 2026
Merck (MRK) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, MRK broke out above the 50-day moving average, suggesting a short
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
08:45am, Friday, 05'th Jun 2026
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Merck: Navigating the Patent Cliff and Future Growth Prospects
07:00pm, Thursday, 04'th Jun 2026
Explore the exciting world of Merck (MRK +4.79%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends an
Merck & Co., Inc. (MRK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
02:52pm, Thursday, 04'th Jun 2026
Merck & Co., Inc. (MRK) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Pfizer vs Merck: Chasing High Yield vs Higher Returns
10:06am, Wednesday, 03'rd Jun 2026
Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly.
Merck & Co., Inc. (MRK) Discusses Oncology Strategy and Program Update With Focus on Clinical Progress and Pipeline Diversification Transcript
Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
06:45am, Tuesday, 02'nd Jun 2026
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference.
Merck's Calderasib Gets FDA's Breakthrough Therapy Tag for NSCLC
02:00pm, Monday, 01'st Jun 2026
MRK wins FDA Breakthrough Therapy designation for calderasib plus Keytruda for certain newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.
